Biopharmaceutical company Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced on Monday that new data has been presented at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference. The data highlights Captisol-enabled Topiramate Injection (IV topiramate) as a potential therapy for neurological conditions, including epilepsy, when oral treatment is impractical.

The presentation showcased modeling and simulations of IV topiramate dosing and preliminary pharmacokinetic data from a clinical study. IV topiramate is designed for hospitalised epilepsy patients and those in emergency care settings who can't take oral topiramate.

Ligand licensed IV topiramate from the University of Minnesota and partnered with CURx Pharmaceuticals for further development. The formulation has received Orphan Drug Designation from the FDA.

Captisol is a patented cyclodextrin technology enabling the solubility and stability of drugs, with several FDA-approved products.

Ligand's business model focuses on financing and licensing technologies to advance drug development, with Captisol as a key platform.